The treatment paradigm for myeloma patients has changed in the last decade with important advancements such as proteasome inhibitors, IMiDS, antibodies and risk-adapted maintenance. How a patient responds to therapy can be used to determine how long the maintenance or follow-up therapy should be. This is called risk-adapted therapy and personalizes myeloma care. The myeloma panel is talking to Dr. Sagar Lonial of Winship Cancer Institute of Emory University, to learn how he uses genetic and disease risk factors to personalize maintenance strategies after stem cell transplants for his patients with multiple myeloma.